Abstract 3042
Background
KS is an HHV8 related lympho-angioproliferative disease with 4 clinical settings: post-transplant, epidemic, endemic, and classic. Although several studies described the clinical course of epidemic and post-transplant KS, the lack of large cohorts of C/E KS precluded such characterization. Our study aimed to describe the clinical course of C/E KS and identify risk factors for systemic treatment (ST) initiation and response.
Methods
We performed a retrospective study including 160C/E KS (n = 131 C and n = 29 E) patients diagnosed between 1990 and 2013 in 1 French dermato-oncology center).
Results
Median age was 62.6years [IQR:54.5;72.4] and Male/Female sex ratio was 140/20. During a median follow-up of 4.8years, 14% patients did not require any treatment while 44 and 41% required local and systemic treatments respectively. Among the 66 patients who required ST, 53% had more than one line of treatment. Cumulative incidence of ST initiation after 2years of follow-up was 28.4% [95%CI:20.5.35.5], and the median time from diagnosis to ST initiation was 8.8years [95%CI:4.7;12.7]. Instantaneous risk of ST initiation decreases over time. Multivariate analysis identified 3 risk factors for ST initiation: E versus C KS (HR: 4.19 [95%CI:2.32; 7.55]), total number of lesions higher than 10 (HR: 4.68 [95%CI:2.47;8.87]), and presence of edema (HR: 1.84 [95%CI:1.02;3.33]). Best overall response (BOR) after the first-line of treatment was CR in 14%, PR in 69%, SD in 8% and PD in 9% patients. Type of first-line therapy (low dose interferon, chemotherapy or other), type of KS (E or C), age at therapy initiation and time between diagnosis and ST initiation were not associated with BOR. Given the chronic evolution of KS and the impact of ST on the quality of life, we evaluated the treatment-free interval (TFI=time between end of first-line and start of second-line) during the first 2years after ST initiation. The mean TFI was 306days [95%CI:199;413] for interferon and 422days [95%CI:320;524] for chemotherapy treated patients.
Conclusions
Our study reveals important ST initiation risk factors in C/E KS. No major efficacy difference was observed between interferon and chemotherapy, thus enabling treatment choice based on patient’s fitness.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract